Kininogen 1在非小细胞肺癌体液和组织中的表达及临床意义

doi:10.3969/j.issn.1006-7795.2021.01.013

首都医科大学学报 ›› 2021, Vol. 42 ›› Issue (1): 77-82.doi: 10.3969/j.issn.1006-7795.2021.01.013

Kininogen 1在非小细胞肺癌体液和组织中的表达及临床意义

王巍伟¹, 王珊珊¹, 张曼^2,3*

1.首都医科大学附属北京世纪坛医院呼吸与危重症医学科, 北京 100038;
2.首都医科大学附属北京世纪坛医院临床检验中心,北京 100038;
3.尿液细胞分子诊断北京市重点实验室, 北京100038

收稿日期:2020-04-21 出版日期:2021-02-21 发布日期:2021-02-02
基金资助:
北京市医院管理局“登峰”人才培养计划(DFL20150701), 尿液细胞分子诊断北京市重点实验室建设经费(2019-JS02)。

Clinical significance of kininogen 1 expression in non-small cell lung cancer biofluids and tissues

Wang Weiwei¹, Wang Shanshan¹, Zhang Man^2,3*

1. Department of Pulmonary and Critical Care Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;
2. Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;
3. Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing 100038, China

Received:2020-04-21 Online:2021-02-21 Published:2021-02-02
Contact: ^*E-mail:zhangman@bjsjth.cn
Supported by:
Beijing Municipal Administration of Hospitals’ Ascent Plan(DFL20150701), Enhancement Funding of Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics(2019-JS02).

摘要/Abstract

摘要： 目的通过检测非小细胞肺癌患者血浆、肺泡灌洗液(bronchoalveolar lavage fluid, BALF)、尿液及组织中激肽原1(kininogen 1,KNG1)的表达,了解其在非小细胞肺癌中的临床意义。方法收集40例非小细胞肺癌患者和20例肺良性疾病对照者的血浆、BALF和尿液标本,通过酶联免疫方法检测血浆、BALF和尿液中KNG1的含量,应用免疫组织化学法检测40例非小细胞肺癌及其癌旁对照标本KNG1的表达。结果非小细胞肺癌患者血浆、BALF和尿液中KNG1浓度显著高于对照组(P均<0.001)。受试者工作特征(receiver operating characteristic,ROC)曲线分析显示KNG1在血浆、肺泡灌洗液和尿液中的曲线下面积分别为0.79、0.89和0.87,差异均有统计学意义(P<0.05),各标本的KNG1均具有一定诊断非小细胞肺癌能力,诊断界值分别为血浆为1 653.6 mg/L,BALF为52.1 mg/L,尿液为2.3 mg/L,尿液的一致性最高(Kappa=0.59),尿液诊断效果优于血浆和BALF。在40例非小细胞肺癌和邻近正常组织中的免疫组织化学染色结果显示非小细胞肺癌组织中KNG1表达高于癌旁正常组织。结论 KNG1在非小细胞肺癌患者的血浆、肺泡灌洗液、尿液和组织中是高表达的,在体液诊断尤其是尿液中具有一定诊断非小细胞肺癌的能力。

关键词: 非小细胞肺癌, 激肽原1, 尿液, 肺泡灌洗液, 组织

Abstract: Objective To evaluate the clinical significance in the diagnosis and prognosis of non-small cell lung cancer (NSCLC) by detecting the expression of kininogen-1 (KNG1) in plasma, alveolar lavage fluid, urine and tissues of patients with NSCLC. Methods The plasma, alveolar lavage fluid and urine samples were collected from 40 patients with NSCLC and 20 patients with benign lung disease (as control group). Enzyme-linked immunosorbent assay was used to detect the content of KNG1 in plasma, bronchoalveolar lavage fluid (BALF) and urine. The expression of KNG1 in 40 NSCLC and its paracancerous control samples was detected by immunohistochemistry. Results The levels of KNG1 in plasma, BALF and urine of patients with NSCLC were significantly higher than those of the control group. Receiver operating characteristic (ROC) curve analysis showed that KNG1 had an area under curve (AUC) of 0.79, 0.89 and 0.87 in plasma, BALF, and urine respectively. All had statistical significance (P<0.05), indicating that KNG1 of each specimen had certain ability to diagnose NSCLC. The diagnostic cut-off values were 1 653.6 mg/L for plasma, 52.1 mg/L for BALF and 2.3 mg/L for urine. The results showed that the consistency of urine was the highest (Kappa=0.59), indicating that the diagnostic effect was better than plasma and BALF. Immunohistochemical staining of 40 NSCLC and adjacent normal tissues showed that KNG1 was higher in NSCLC tissues than in adjacent normal tissues. Conclusions KNG1 was highly expressed in plasma, alveolar lavage fluid, urine and tissues of NSCLC, and had a certain ability to diagnose NSCLC in body fluids, especially urine.

Key words: non-small cell lung cancer, kininogen 1, urine, bronchoalveolar lavage fluid(BALF), tissue

中图分类号:

R734.2

王巍伟, 王珊珊, 张曼. Kininogen 1在非小细胞肺癌体液和组织中的表达及临床意义[J]. 首都医科大学学报, 2021, 42(1): 77-82.

Wang Weiwei, Wang Shanshan, Zhang Man. Clinical significance of kininogen 1 expression in non-small cell lung cancer biofluids and tissues[J]. Journal of Capital Medical University, 2021, 42(1): 77-82.

参考文献

[1] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019[J]. CA: Cancer J Clin, 2019, 69(1): 7-34.
[2] Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(Pt 1): 103-109.
[3] Wang W, Wang S, Zhang M. Identification of urine biomarkers associated with lung adenocarcinoma[J]. Oncotarget, 2017, 8(24): 38517-38529.
[4] Sim S Y, Choi Y R, Lee J H,et al. In-depth proteomic analysis of human bronchoalveolar lavage fluid toward the biomarker discovery for lung cancers[J]. Proteom Clin Appl, 2019, 13(5): e1900028.
[5] Sharp C N, Korte E A, Hosseineja D K, et al. ELISA-based detection of open reading frame protein 1 in patients at risk of developing lung cancer [J]. Clin Chim Acta, 2020, 507:1-6.
[6] Abdul-Rahman P S, Lim B K, Hashim O H. Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods [J]. Electrophoresis, 2007, 28(12): 1989-1996.
[7] Wang J, Wang X, Lin S, et al. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer [J]. PLoS One, 2013, 8(7): e70519.
[8] Yu J S, Chen Y T, Chiang W F, et al. Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan[J]. Proceed Natl Acad Sci U S A, 2016, 113(41): 11549-11554.
[9] Kay FU, Kandathil A, Batra K, et al. Revisions to the tumor, node,metastasis staging of lung cancer (8th edition): rationale, radiologic findings and clinical imply cations[J]. World J Radiol, 2017, 9(6): 269-279.
[10]Yu S, Meng Q, Hu H, et al. Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer[J]. Int J Clin Exp Pathol, 2014, 7(9): 5538-5548.
[11]Doustjalali S R, Yusof R, Yip C H, et al. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors [J]. Electrophoresis, 2004, 25(14): 2392-2401.
[12]Mu A K, Lim B K, Hashim O H, et al. Identification of O-glycosylated proteins that are aberrantly excreted in the urine of patients with early stage ovarian cancer [J]. Int J Mol Sci, 2013, 14(4): 7923-7931.
[13]Sandim V, Pereira Dde A, Kalume D E, et al. Proteomic
analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma [J]. Urol Oncol, 2016, 34(1): e11-e25.
[14]Xu J, Fang J, Cheng Z, et al. Overexpression of the Kininogen-1 inhibits proliferation and induces apoptosis of glioma cells[J]. J Exp Clin Cancer Res, 2018, 37(1): 180.
[15]Schrodter S, Braun M, Syring I, et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma[J]. Mol Cancer, 2016, 15: 10.
[16]Jiang W, Zhang L, Guo Q, et al. Identification of the pathogenic biomarkers for hepatocellular carcinoma based on RNA-seq analyses[J]. Pathol Oncol Res, 2019, 25(3):1207-1213.
[17]Liu W, Liu B, Cai Q, et al. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis [J]. Clin Chim Acta, 2012, 413(13-14): 1098-1106.
[18]Quesada-Calvo F, Massot C, Bertrand V, et al. OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages [J]. Clin Proteomics, 2017, 14: 9.
[19]Gao B, Yu T, Xue D, et al. A multidimensional integration analysis reveals potential bridging targets in the process of colorectal cancer liver metastasis [J]. PLoS One, 2017, 12(6): e0178760.
[20]Navaneethan U, Lourdusamy V, Gk Venkatesh P, et al. Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study[J]. Gastroenterol Rep, 2015, 3(2): 136-143.
[21]Huang D, Yuan W, Li H, et al. Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis [J]. Exp Ther Med, 2018, 16(3): 1850-1858.

Kininogen 1在非小细胞肺癌体液和组织中的表达及临床意义

Clinical significance of kininogen 1 expression in non-small cell lung cancer biofluids and tissues

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张丽, 李兵, 童冠圣. 基于¹⁸F-FDG代谢显像的腹膜假黏液瘤PCI评分及肿瘤分级预测[J]. 首都医科大学学报, 2022, 43(6): 834-839.
[2]	李颖, 陈彪, 王乃利, 郝欣平. 人体内耳冰冻切片免疫组织化学染色技术探讨[J]. 首都医科大学学报, 2022, 43(6): 905-910.
[3]	李云飞, 黄晓武, 夏恩兰. 经阴道内镜手术在无性生活生育年龄女性子宫内病变的临床应用[J]. 首都医科大学学报, 2022, 43(4): 658-663.
[4]	程姣姣, 阮祥燕, 杜娟, 谷牧青. 未成熟卵母细胞体外成熟在生育力保护中的应用进展[J]. 首都医科大学学报, 2022, 43(3): 329-335.
[5]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[6]	李云飞, 夏恩兰, 黄晓武. 绝经后异常子宫出血患者的临床与病理分析[J]. 首都医科大学学报, 2021, 42(6): 1060-1064.
[7]	谭晓刚, 张毅. 新辅助免疫治疗在可切除非小细胞肺癌中的应用前景[J]. 首都医科大学学报, 2021, 42(5): 862-867.
[8]	程姣姣, 阮祥燕, 杜娟, 金凤羽, 李扬璐, 谷牧青. 卵巢组织冻存移植安全性的研究进展[J]. 首都医科大学学报, 2021, 42(4): 505-510.
[9]	金凤羽, 阮祥燕, 杜娟, 程姣姣, 李扬璐, 王虎生, 谷牧青, 鞠蕊, 杨瑜, 王月姣, 许新. 中国首个卵巢组织冻存库冻存患者特征及冻存效果分析[J]. 首都医科大学学报, 2021, 42(4): 521-525.
[10]	武永乐, 尚宏伟, 孙广永, 张栋, 丁惠国. 小鼠脂肪组织中免疫细胞分离方法的优化及亚群在肥胖小鼠中的作用[J]. 首都医科大学学报, 2021, 42(4): 559-567.
[11]	邓会, 王勇, 陈小兰, 秦崇, 潘磊. 不同时间低压低氧刺激对大鼠肺动脉压力及肺组织的影响[J]. 首都医科大学学报, 2021, 42(4): 596-600.
[12]	刘怡均, 林向英, 张燕. 中文版世界卫生组织生存质量测定量表简表用于终末期肾病的信效度验证[J]. 首都医科大学学报, 2021, 42(4): 635-641.
[13]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[14]	李沛霖, 崔磊. 真皮内脂肪组织调控皮肤生理病理过程与机制的研究进展[J]. 首都医科大学学报, 2020, 41(6): 896-900.
[15]	胡磊, 周建, 王劲松. 坚持、坚守、坚定的拓路者——中国科学院院士王松灵教授[J]. 首都医科大学学报, 2020, 41(5): 724-729.